Targets › CHRM2
18 programs from 17 companies in 125 trials: 45 Phase 3, 30 Phase 4, 29 Phase 2, 21 Phase 1; Other, Genitourinary, Neurology; next expected readout Nov 2026.
Muscarinic receptor for acetylcholine, a neurotransmitter found in the brain, neuromuscular junctions and the autonomic ganglia. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. (UniProt, P08172)
Open in Phaseline: the race on CHRM2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | Trospium Chloride Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 4 | Schizophrenia; Bipolar-I Disorder With Mania or Mania With Mixed Features; Bipolar Disorder Type I With Mania or Mania With Mixed Features; Mania … | Nov 2026 |
| Bristol-Myers Squibb | Trospium Chloride (BMS-986510) Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 4 | Healthy Volunteers; Psychosis Associated With Alzheimer's Disease; Alzheimer Disease; Schizophrenia | Nov 2026 |
| University of California, San Francisco | Intravenous TXA Interleukin-23 inhibitor | ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4 | Phase 4 | Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke … | Dec 2026 |
| Mackay Memorial Hospital | Solifenacin Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 4 | Effect of Drug; Urinary Bladder, Overactive | Dec 2026 |
| Mansoura University | Solifenacin succinate Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 4 | Overactive Bladder (OAB); Nocturnal Enuresis in Children | Jun 2027 |
| University of Aarhus | Solifenacin Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 4 | Urinary Incontinence in Children | Oct 2027 |
| University of California, Davis | Oxybutynin Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 3 | Overactive Bladder Syndrome | Dec 2026 |
| Bir Hospital | Solifenacin Succinate Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 3 | Ureteral Stent-Related Symptom | Dec 2026 |
| Ocus Innovation Ireland | Atropine Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM1, CHRM2 | Phase 3 | Myopia | Dec 2027 |
| Central Hospital, Nancy, France | Oxybutynin Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 3 | Spina Bifida | Jan 2028 |
| Sherief Abd-Elsalam | orphenadrine Anticholinergic drug with CNS and peripheral activity; used for muscle spasms and pain | CHRM1, CHRM2, CHRM3 | Phase 3 | Liver Cirrhosis | Dec 2028 |
| Reinier de Graaf Groep | Oxybutynin Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 3 | Breast Cancer | Jan 2029 |
| Zhaoke (Guangzhou) Ophthalmology Pharmaceutical | Atropine Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM1, CHRM2 | Phase 3 | Myopia; Achalasia; Progressive Myopia; Focus on Axial Length … | – |
| Belfast Health and Social Care Trust | Atropine Sulfate Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM1, CHRM2 | Phase 2 | Myopia | Feb 2027 |
| Oliver Blanchard | Darifenacin Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 2 | Amyotrophic Lateral Sclerosis | Oct 2027 |
| University Hospital, Bordeaux | Oxybutynin Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 2 | Male Urogenital Diseases | Feb 2028 |
| AstraZeneca | Glycopyrronium Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor | CHRM3, CHRM1, CHRM4, CHRM2, CHRM5 | Phase 2 | Asthma | May 2029 |
| University of Arizona | Oxybutynin Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 2 | Obstructive Sleep Apnea | – |
Myopia (17) Schizophrenia (6) Alzheimer Disease (4) Healthy Volunteers (4) Alzheimer's Disease (3) Psychosis Associated With Alzheimer's Disease (3) Nicotine Dependence (3) Progressive Myopia (2) Myopia, Progressive (2) Urinary Incontinence in Children (2) Breast Cancer (2) Psoriasis Vulgaris (2)
small molecule (16), protein or peptide (1)
Bristol-Myers Squibb (2) Zhaoke (Guangzhou) Ophthalmology Pharmaceutical (1) University of Arizona (1) Bir Hospital (1) University of Aarhus (1) Reinier de Graaf Groep (1) Ocus Innovation Ireland (1) University Hospital, Bordeaux (1) University of California, San Francisco (1) Belfast Health and Social Care Trust (1) Mackay Memorial Hospital (1) Central Hospital, Nancy, France (1) Oliver Blanchard (1) AstraZeneca (1) Mansoura University (1) Sherief Abd-Elsalam (1) University of California, Davis (1)
CHRM3 (18) CHRM1 (5) ADRB2 (1) AGTR1 (1) IL12B (1) IL23A (1) PDCD1 (1) NR3C1 (1) HTR2A (1) MAP2K1 (1) MAP2K2 (1) MS4A1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.